MedTrace Logo

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

NCT06493760 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-09-19

No results posted yet for this study

Summary

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Conditions

Interventions

DRUG

SSGJ-707

bispecific antibody

DRUG

Bevacizumab

VEGF antibody

DRUG

Oxaliplatin

chemotherapy

DRUG

Capecitabine

chemotherapy

DRUG

Calcium Folinate

chemotherapy

DRUG

5-fluorouracil

chemotherapy

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2025-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06493760 on ClinicalTrials.gov